Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

TMC-310911

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
TMC-310911
Legal status
Legal status
Identifiers
  • [(3As,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl]N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC38H53N5O7S2
Molar mass755.99 g·mol−1
3D model (JSmol)
  • CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
  • InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1
  • Key:JQUNFHFWXCXPRK-AMMMHQJVSA-N

TMC-310911 (also known asASC-09) is anantiviral drug which was originally researched as a treatment forHIV/AIDS. It is aprotease inhibitor related todarunavir.[1][2] While TMC-310911 was not ultimately developed as a medication for the treatment of AIDS, research has continued into potential applications in the treatment of other viral diseases, and in March 2020 it was entered intoclinical trials for the treatment ofCOVID-19.[3][4]

See also

[edit]

References

[edit]
  1. ^Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G (December 2011)."TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors".Antimicrobial Agents and Chemotherapy.55 (12):5723–31.doi:10.1128/AAC.00748-11.PMC 3232804.PMID 21896904.
  2. ^Ghosh AK, Brindisi M (April 2015)."Organic carbamates in drug design and medicinal chemistry".Journal of Medicinal Chemistry.58 (7):2895–940.doi:10.1021/jm501371s.PMC 4393377.PMID 25565044.
  3. ^Catapang JK, Billones JB (March 2020)."On the Generation of Novel Ligands for SARS-CoV-2 Protease and ACE2 Receptor via Constrained Graph Variational Autoencoders".ChemRxiv.doi:10.26434/chemrxiv.12011157.v3.
  4. ^McGrath J (2 April 2020)."All the COVID-19 vaccines and treatments currently in clinical trials". Digital Trends. Retrieved6 April 2020.
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1st generation
2nd generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1st generation
2nd generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHSrecommendedinitial regimen options.◊Formerly or rarely used agent.
Retrieved from "https://en.wikipedia.org/w/index.php?title=TMC-310911&oldid=1215136392"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp